Heart FailureFIND HF LOOPNCT07320677
Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey
A study testing NT-proBNP screening in people with Heart Failure and Diuretics, run by Government of Jersey at 1 site in Jersey.
Trial summary
The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Heart Failure, Diuretics
- What is being tested?
- NT-proBNP screening
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- 1 siteJersey
- Study dates
- 1 Nov 2025to Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Receiving a loop diuretic (furosemide, bumetanide or torsemide)
- No coded diagnosis of heart failure in GP records
- Never had a natriuretic peptide test
- Willing to have a blood test for NT-proBNP
Who cannot join
- Clinical Frailty Score 7 or above on Rockwood frailty scale
- Prior diagnosis of heart failure
- Prior natriuretic peptide testing
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Jersey1 site
Jersey General Hospital
Saint Helier
About this study
Official title: Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey (FIND-HF LOOP)
The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure.
The main questions it aims to answer are:
Read more
- Does offering a NT-proBNP blood test to eligible patients increase the number of new heart failure diagnoses within 12 months compared with usual care?
- Does this screening pathway also uncover other important heart problems, such as irregular heart rhythms (arrhythmias) or valve disease?
This is a cluster randomised controlled trial, which means that whole GP practices, rather than individual patients, are randomly assigned to one of two approaches:
- NT-proBNP screening pathway, in which eligible patients are invited for a NT-proBNP blood test
- Usual care, in which patients continue to be managed as they normally would without proactive screening
Participants will:
Be identified from GP records if they are prescribed loop diuretics and have no prior diagnosis of heart failure
In screening practices, be invited to attend for a free finger-prick NT-proBNP blood test and brief questionnaire
Be referred to the heart failure team and invited for an echocardiogram (a heart ultrasound scan) and further assessment if their NT-proBNP level is higher than 125 pg/mL
Researchers will compare outcomes between screening and usual-care practices after 12 months, focusing on new diagnoses of heart failure. They will also look at other important cardiovascular findings, such as new arrhythmias, valve disease, and heart failure hospitalisation rates.
- Conditions
- Heart Failure, Diuretics
- Being tested
- NT-proBNP screening
- Keywords
- NT-proBNP, Natriuretic peptide, Heart Failure, Screening
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NT-proBNP screeningDiagnostic test
Patients in the intervention arm will be invited for a free point of care NT-proBNP blood test
| Study group | Role | What they receive |
|---|---|---|
| Intervention - NTproBNP Screening | Experimental | Half of the island's GP surgeries will be randomly allocated to the intervention arm, whereby patients receiving a loop diuretic but without a diagnosis of heart failure or natriuretic peptide testing will be invited for a point of care NT-proBNP test. Receives: Diagnostic Test: NT-proBNP screening |
| Control - Usual care | No intervention | Half of the island's GP surgeries will be randomly allocated to the control arm, whereby patients will continue with usual clinical care and won't be approached by the study team. |
What is being measured
The primary outcome is the main question the study is designed to answer.
New Heart Failure diagnosis at 12 months
Measured: 12 months from practice enrollment
Secondary outcomes (3)
New clinically relevant cardiovascular disease
This will include moderate valvular disease and arrhythmia (eg, AF).
Measured: 12 months
Heart Failure Hospitalisations
Measured: 12 months
All cause mortality
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jan 2026
- Study start1 Nov 2025
- Primary completionMar 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Heart FailureStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Government of Jersey
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Aaron Henry, Government of Jersey
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07320677
- Sponsor's protocol ID
- 2025HCJREC03
- Acronym
- FIND HF LOOP
- Status last verified
- Dec 2025
- First submitted
- 22 Dec 2025
- Last updated
- 6 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Finding Heart Failure in Those Prescribed Loop Diuretics in Primary Care in Jersey (FIND-HF LOOP)
- ClinicalTrials.gov ID
- NCT07320677
- Acronym / sponsor ID
- FIND HF LOOP / 2025HCJREC03
- Conditions
- Heart Failure, Diuretics
- Keywords
- NT-proBNP, Natriuretic peptide, Heart Failure, Screening
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Government of JerseyOther government
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Jul 2027 (estimated)
- First posted
- 6 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether a simple blood test screening pathway can help diagnose heart failure earlier in adults in primary care who take loop diuretic medicines (such as furosemide or bumetanide) but do not have a recorded diagnosis of heart failure.
The main questions it aims to answer are:
- Does offering a NT-proBNP blood test to eligible patients increase the number of new heart failure diagnoses within 12 months compared with usual care?
- Does this screening pathway also uncover other important heart problems, such as irregular heart rhythms (arrhythmias) or valve disease?
This is a cluster randomised controlled trial, which means that whole GP practices, rather than individual patients, are randomly assigned to one of two approaches:
- NT-proBNP screening pathway, in which eligible patients are invited for a NT-proBNP blood test
- Usual care, in which patients continue to be managed as they normally would without proactive screening
Participants will:
Be identified from GP records if they are prescribed loop diuretics and have no prior diagnosis of heart failure
In screening practices, be invited to attend for a free finger-prick NT-proBNP blood test and brief questionnaire
Be referred to the heart failure team and invited for an echocardiogram (a heart ultrasound scan) and further assessment if their NT-proBNP level is higher than 125 pg/mL
Researchers will compare outcomes between screening and usual-care practices after 12 months, focusing on new diagnoses of heart failure. They will also look at other important cardiovascular findings, such as new arrhythmias, valve disease, and heart failure hospitalisation rates.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention - NTproBNP Screening | Experimental | Diagnostic Test: NT-proBNP screeningHalf of the island's GP surgeries will be randomly allocated to the intervention arm, whereby patients receiving a loop diuretic but without a diagnosis of heart failure or natriuretic peptide testing will be invited for a point of care NT-proBNP test. |
| Control - Usual care | No intervention | –Half of the island's GP surgeries will be randomly allocated to the control arm, whereby patients will continue with usual clinical care and won't be approached by the study team. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Receiving a loop diuretic (furosemide, bumetanide or torsemide)
- No coded diagnosis of heart failure in GP records
- Never had a natriuretic peptide test
- Willing to have a blood test for NT-proBNP
Key exclusion criteria (3 listed)
- Clinical Frailty Score 7 or above on Rockwood frailty scale
- Prior diagnosis of heart failure
- Prior natriuretic peptide testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NT-proBNP screeningPatients in the intervention arm will be invited for a free point of care NT-proBNP blood test | Diagnostic test | Intervention - NTproBNP Screening |
Primary outcome
New Heart Failure diagnosis at 12 months
Time frame: 12 months from practice enrollment
3 secondary outcomes
New clinically relevant cardiovascular disease
Time frame: 12 months
Heart Failure Hospitalisations
Time frame: 12 months
All cause mortality
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jan 2026.
Related trials for Heart Failure
Recruiting
ELEVATE-HFpEF Clinical Study
Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
Heart@Home Safety and Efficacy of Hospital-at-Home Care Versus Standard Hospitalization in Cardiac Patients
Myocardial Infarction, Myocarditis Acute
Recruiting
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Heart Failure, Heart Failure NYHA Class II
RecruitingObservational study
31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum
Cardiomyopathies, Heart Failure
Not yet recruiting
Importance of Point-of-Care Ultrasound for Early Detection of Valvular and Cardiac Diseases (IMPROVE)
Valvular Heart Disease Patients, Aortic Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NT-proBNP screening in people with Heart Failure and Diuretics, run by Government of Jersey at 1 site in Jersey.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 6 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Jersey. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
New Heart Failure diagnosis at 12 months (time frame: 12 months from practice enrollment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jan 2026.